Clinical Trials Browser

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07187960 2025-09-23

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

Phase 3 Not yet recruiting

228 enrolled

Lymphoid

Lymphoma, Follicular

NCT07169565 2025-09-11

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Phase 1 Not yet recruiting

21 enrolled

Lymphoid

Waldenstrom Macroglobulinemia

NCT07159906 2025-09-08

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1/2 Not yet recruiting

62 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT07034508 2025-06-24

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Phase 2 Not yet recruiting

134 enrolled

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT06973811 2025-05-20

ZR-MTX

Phase 2 Not yet recruiting

47 enrolled

Lymphoid

Intraocular Lymphoma

NCT06942507 2025-04-30

BRZ-WM

Phase NA Not yet recruiting

104 enrolled

Lymphoid

Waldenstrom Macroglobulinemia

NCT06557330 2025-01-06

MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

Phase 2 Not yet recruiting

24 enrolled

Lymphoid

Lymphoma

NCT06573645 2024-08-27

A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL

Phase 3 Not yet recruiting

428 enrolled

Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06516978 2024-07-24

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Phase 2 Not yet recruiting

528 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06441097 2024-06-04

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Phase 2 Not yet recruiting

152 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05990985 2023-08-18

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Phase NA Not yet recruiting

20 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05280626 2022-03-15

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Phase 2 Not yet recruiting

100 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04913103 2021-06-04

CLSGMCLPOLA

Phase 2 Not yet recruiting

21 enrolled

Lymphoid

Lymphoma, Mantle-Cell

Clinical Trials

Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma

ZBR in WM

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

ZR-MTX

BRZ-WM

MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

CLSGMCLPOLA